{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:41:43Z","timestamp":1788536503116,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Egyptian Russian University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Many COVID-19 sufferers have a history of cardiovascular illnesses, which makes them more likely to develop severe COVID-19. Such patients were advised by experts to prioritize drug therapies based on their doctor\u2019s commendations to avoid exacerbating their basic illnesses. Therefore, developing an analytical methodology for the concurrent estimation of medications prescribed for co-treating cardiovascular and COVID-19 illnesses is becoming critical in both bioavailability hubs and QC units. Herein, an inventive, rapid, and affordable HPTLC approach was developed, and its conditions were optimized employing the full factorial design approach for the concurrent estimation of aspirin, atorvastatin, atenolol, losartan, remdesivir, and favipiravir as co-administered medications, either with salicylic acid or not. Using the desirability function, the experimental design approach could forecast the best eluent system for optimal resolution results. On HPTLC-silica plates, the above-mentioned medications were separated utilizing an eluent system of ethyl acetate, methylene chloride, methanol, and ammonia (6:4:4:1 by volume), and their spots were detected at 232\u00a0nm. The proposed methodology was evaluated following ICH prerequisites and applied successfully to the medications\u2019 dosage forms, human plasma, and buffered dissolution media with superb recovery proportions and no intrusiveness from formulations\u2019 additives or plasma matrices. Five metrics were employed to appraise the suggested technique\u2019s greenness: AGREE, eco-scale, Raynie and Driver, GAPI, and NEMI. The sensitivity, large sample capacity, and short run duration (15\u00a0min) of the proposed methodology confirm its appositeness for regular estimation of the above-mentioned medications.<\/jats:p>","DOI":"10.1038\/s41598-024-83692-x","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T18:57:45Z","timestamp":1740077865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["QbD-steered HPTLC approach for concurrent estimation of six co-administered COVID-19 and cardiovascular drugs in different matrices: greenness appraisal"],"prefix":"10.1038","volume":"15","author":[{"given":"Ahmed R.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania A.","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalla","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"83692_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-021-10429-0","volume":"21","author":"M Amini","year":"2021","unstructured":"Amini, M., Zayeri, F. & Salehi, M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. BMC Public Health. 21, 1\u201312 (2021).","journal-title":"BMC Public Health"},{"key":"83692_CR2","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","volume":"390","author":"M Naghavi","year":"2017","unstructured":"Naghavi, M., Abajobir, A. A., Abbafati, C. & Abbas, K. M. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet 390, 1151\u20131210 (2017).","journal-title":"Lancet"},{"key":"83692_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","volume":"70","author":"GA Roth","year":"2017","unstructured":"Roth, G. A., Johnson, C., Abajobir, A. & Abd-Allah, F. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol. 70, 1\u201325 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"83692_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin, E. J., Blaha, M. J., Chiuve, S. E. & Cushman, M. Heart disease and stroke statistics\u20142017 update: a report from the American Heart Association. Circulation 135, 146\u2013603 (2017).","journal-title":"Circulation"},{"key":"83692_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/ncpcardio1438","volume":"6","author":"D Xavier","year":"2009","unstructured":"Xavier, D., Pais, P., Sigamani, A. & Pogue, J. The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study. Nat. Clin. Pract. Cardiovasc. Med. 6, 96\u201397 (2009).","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"83692_CR6","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jacc.2014.08.021","volume":"64","author":"JM Castellano","year":"2014","unstructured":"Castellano, J. M., Sanz, G., Pe\u00f1alvo, J. L. & Bansilal, S. A polypill strategy to improve adherence: results from the FOCUS project. J. Am. Coll. Cardiol. 64, 2071\u20132082 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"83692_CR7","doi-asserted-by":"publisher","first-page":"100500","DOI":"10.1016\/j.hlpt.2021.02.006","volume":"10","author":"LCA Esba","year":"2021","unstructured":"Esba, L. C. A., Yousef, C., Ismail, S. & Halim, M. Fixed dose combinations: a formulary decision guide. Heal Policy Technol. 10, 100500 (2021).","journal-title":"Heal Policy Technol."},{"key":"83692_CR8","first-page":"215","volume":"18","author":"Q Salako","year":"1989","unstructured":"Salako, Q., Fadiran, E. O. & Thomas, W. O. Detection and determination of salicylic acid impurity in aspirin tablet formulations\u2019 by high performance liquid chromatography. Afr. J. Med. Med. Sci. 18, 215\u2013218 (1989).","journal-title":"Afr. J. Med. Med. Sci."},{"key":"83692_CR9","unstructured":"Coronavirus disease. 2019 (COVID-19) Treatment Guidelines (National Institutes of Health, 2022)."},{"key":"83692_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/separations8120243","volume":"8","author":"AE Ibrahim","year":"2021","unstructured":"Ibrahim, A. E., El Deeb, S., Abdelhalim, E. M., Al-Harrasi, A. & Sayed, R. A. Green stability indicating organic solvent-free HPLC determination of remdesivir in substances and pharmaceutical dosage forms. Separations 8, 243 (2021).","journal-title":"Separations"},{"key":"83692_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijsu.2020.02.034","volume":"76","author":"C Sohrabi","year":"2020","unstructured":"Sohrabi, C., Alsafi, Z., O\u2019neill, N. & Khan, M. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int. J. Surg. 76, 71\u201376 (2020).","journal-title":"Int. J. Surg."},{"key":"83692_CR12","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.3390\/molecules27123658","volume":"27","author":"AE Ibrahim","year":"2022","unstructured":"Ibrahim, A. E., Sharaf, Y. A., El Deeb, S. & Sayed, R. A. Analytical performance and greenness evaluation of five multi-level design models utilized for impurity profiling of favipiravir, a promising COVID-19 antiviral drug. Molecules 27, 3658 (2022).","journal-title":"Molecules"},{"key":"83692_CR13","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.3390\/molecules27072330","volume":"27","author":"YA Sharaf","year":"2022","unstructured":"Sharaf, Y. A., El Deeb, S., Ibrahim, A. E., Al-Harrasi, A. & Sayed, R. A. Two green micellar HPLC and mathematically assisted UV spectroscopic methods for the simultaneous determination of molnupiravir and favipiravir as a novel combined COVID-19 antiviral regimen. Molecules 27, 2330 (2022).","journal-title":"Molecules"},{"key":"83692_CR14","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.numecd.2020.04.001","volume":"30","author":"G Li","year":"2020","unstructured":"Li, G., Hu, R. & Gu, X. A close-up on COVID-19 and cardiovascular diseases. Nutr. Metab. Cardiovasc. Dis. 30, 1057\u20131060 (2020).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"83692_CR15","doi-asserted-by":"publisher","first-page":"104949","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104949","volume":"29","author":"R Pranata","year":"2020","unstructured":"Pranata, R., Huang, I., Lim, M. A., Wahjoepramono, E. J. & July, J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19\u2013systematic review, meta-analysis, and meta-regression. J. Stroke Cerebrovasc. Dis. 29, 104949 (2020).","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"83692_CR16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","volume":"397","author":"OJ Wouters","year":"2021","unstructured":"Wouters, O. J. et al. Jit, M. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet 397, 1023\u20131034 (2021).","journal-title":"Lancet"},{"key":"83692_CR17","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/cbic.202000595","volume":"22","author":"O Sreekanth Reddy","year":"2021","unstructured":"Sreekanth Reddy, O., Lai, W. & Tackling COVID-19 using remdesivir and favipiravir as therapeutic options. ChemBioChem 22, 939\u2013948 (2021).","journal-title":"ChemBioChem"},{"key":"83692_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/cpt.1844","volume":"108","author":"Y Du","year":"2020","unstructured":"Du, Y. & Chen, X. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin. Pharmacol. Ther. 108, 242\u2013247 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"83692_CR19","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","volume":"295","author":"CJ Gordon","year":"2020","unstructured":"Gordon, C. J. et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 295, 6785\u20136797 (2020).","journal-title":"J. Biol. Chem."},{"key":"83692_CR20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/10826076.2011.601495","volume":"35","author":"NM Bhatia","year":"2012","unstructured":"Bhatia, N. M., Gurav, S. B., Jadhav, S. D. & Bhatia, M. S. RP-HPLC method for simultaneous estimation of atorvastatin calcium, losartan potassium, atenolol, and aspirin from tablet dosage form and plasma. J. Liq Chromatogr. Relat. Technol. 35, 428\u2013443 (2012).","journal-title":"J. Liq Chromatogr. Relat. Technol."},{"key":"83692_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/chemosensors11010025","volume":"11","author":"B \u017buromska-Witek","year":"2023","unstructured":"\u017buromska-Witek, B., Stolarczyk, M., Szl\u00f3sarczyk, M., Kielar, S. & Hubicka, U. Simple, accurate and multianalyte determination of thirteen active pharmaceutical ingredients in Polypills by HPLC-DAD. Chemosensors 11, 25 (2023).","journal-title":"Chemosensors"},{"key":"83692_CR22","doi-asserted-by":"publisher","first-page":"121625","DOI":"10.1016\/j.saa.2022.121625","volume":"281","author":"S Ramzy","year":"2022","unstructured":"Ramzy, S., Abdelazim, A. H., Osman, A. O. E. & Hasan, M. A. Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human plasma. Spectrochim Acta Part. Mol. Biomol. Spectrosc. 281, 121625 (2022).","journal-title":"Spectrochim Acta Part. Mol. Biomol. Spectrosc."},{"key":"83692_CR23","doi-asserted-by":"publisher","first-page":"107101","DOI":"10.1016\/j.microc.2021.107101","volume":"174","author":"DAM Noureldeen","year":"2022","unstructured":"Noureldeen, D. A. M., Boushra, J. M., Lashien, A. S., Hakiem, A. F. A. & Attia, T. Z. Novel environment friendly TLC-densitometric method for the determination of anti-coronavirus drugs Remdesivir and Favipiravir: Green assessment with application to pharmaceutical formulations and human plasma. Microchem J. 174, 107101 (2022).","journal-title":"Microchem J."},{"key":"83692_CR24","doi-asserted-by":"publisher","first-page":"107580","DOI":"10.1016\/j.microc.2022.107580","volume":"179","author":"AA Emam","year":"2022","unstructured":"Emam, A. A., Abdelaleem, E. A., Abdelmomen, E. H., Abdelmoety, R. H. & Abdelfatah, R. M. Rapid and ecofriendly UPLC quantification of Remdesivir, Favipiravir and Dexamethasone for accurate therapeutic drug monitoring in Covid-19 patient\u2019s plasma. Microchem J. 179, 107580 (2022).","journal-title":"Microchem J."},{"key":"83692_CR25","doi-asserted-by":"publisher","first-page":"107321","DOI":"10.1016\/j.microc.2022.107321","volume":"178","author":"NF El Azab","year":"2022","unstructured":"El Azab, N. F. A validated UHPLC-MS\/MS method for simultaneous quantification of some repurposed COVID-19 drugs in rat plasma: application to a pharmacokinetic study. Microchem J. 178, 107321 (2022).","journal-title":"Microchem J."},{"key":"83692_CR26","doi-asserted-by":"publisher","first-page":"113935","DOI":"10.1016\/j.jpba.2021.113935","volume":"196","author":"K Habler","year":"2021","unstructured":"Habler, K. et al. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC\u2013MS\/MS method in human serum. J. Pharm. Biomed. Anal. 196, 113935 (2021).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"83692_CR27","first-page":"1","volume":"54","author":"IM Fukuda","year":"2018","unstructured":"Fukuda, I. M., Pinto, C. F. F., Moreira, C. S., Saviano, A. M. & Louren\u00e7o, F. R. Design of experiments (DoE) applied to pharmaceutical and analytical quality by design (QbD). Brazilian J. Pharm. Sci. 54, 1\u201316 (2018).","journal-title":"Brazilian J. Pharm. Sci."},{"key":"83692_CR28","first-page":"272","volume":"11","author":"M Deepa","year":"2017","unstructured":"Deepa, M., Reddy, K. R. & Satyanarayana, S. V. A review on quality by design approach for analytical method development. J. Pharm. Res. 11, 272\u2013277 (2017).","journal-title":"J. Pharm. Res."},{"key":"83692_CR29","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s10895-022-02942-1","volume":"32","author":"AR Mohamed","year":"2022","unstructured":"Mohamed, A. R. Utility of silver-nanoparticles for Nano-fluorimetric determination of vancomycin hydrochloride in pharmaceutical formulation and biological fluids: Greenness assessment. J. Fluoresc. 32, 1899\u20131912 (2022).","journal-title":"J. Fluoresc"},{"key":"83692_CR30","unstructured":"FDA-recommended dissolution methods. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/dissolution\/"},{"key":"83692_CR31","doi-asserted-by":"publisher","first-page":"100694","DOI":"10.1016\/j.scp.2022.100694","volume":"27","author":"RA Sayed","year":"2022","unstructured":"Sayed, R. A., Mohamed, A. R., Hassan, W. S. & Elmasry, M. S. Earth-friendly-assessed chromatographic platforms for rapid analysis of sulfacetamide sodium and prednisolone acetate in presence of sulfanilamide impurity: application on ophthalmic formulation and aqueous humor. Sustain. Chem. Pharm. 27, 100694 (2022).","journal-title":"Sustain. Chem. Pharm."},{"key":"83692_CR32","unstructured":"ICH. Q2A (R1). Validation of analytical procedures: text and methodology, in International Conference on Harmonization (IFPMA, 2005)."},{"key":"83692_CR33","doi-asserted-by":"crossref","unstructured":"Variyar, P. S., Chatterjee, S. & Sharma, A. High-Performance Thin-Layer Chromatography (HPTLC) 27\u201339. (Springer, 2011).","DOI":"10.1007\/978-3-642-14025-9_2"},{"key":"83692_CR34","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1080\/03639045.2021.2001490","volume":"47","author":"RA Sayed","year":"2021","unstructured":"Sayed, R. A., Mohamed, A. R., Hassan, W. S. & Elmasry, M. S. Smart UV-spectrophotometric platforms for rapid green analysis of miconazole nitrate and nystatin in their combined suppositories and in vitro dissolution testing. Drug Dev. Ind. Pharm. 47, 1469\u20131480 (2021).","journal-title":"Drug Dev. Ind. Pharm."},{"key":"83692_CR35","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/jaoacint\/qsac074","volume":"105","author":"AR Mohamed","year":"2022","unstructured":"Mohamed, A. R., Abolmagd, E., Badrawy, M. & Nour, I. M. Innovative earth-friendly UV-spectrophotometric technique for in-vitro dissolution testing of miconazole nitrate and nystatin in their vaginal suppositories: greenness assessment. J. AOAC Int. 105, 1528\u20131535 (2022).","journal-title":"J. AOAC Int."},{"key":"83692_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.trac.2012.03.013","volume":"37","author":"A Ga\u0142uszka","year":"2012","unstructured":"Ga\u0142uszka, A., Migaszewski, Z. M., Konieczka, P. & Namie\u015bnik, J. Analytical Eco-scale for assessing the greenness of analytical procedures. TrAC Trends Anal. Chem. 37, 61\u201372 (2012).","journal-title":"TrAC Trends Anal. Chem."},{"key":"83692_CR37","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1021\/cr068359e","volume":"107","author":"LH Keith","year":"2007","unstructured":"Keith, L. H., Gron, L. U. & Young, J. L. Green analytical methodologies. Chem. Rev. 107, 2695\u20132708 (2007).","journal-title":"Chem. Rev."},{"key":"83692_CR38","unstructured":"Raynie, D. & Driver, J. Green assessment of chemical methods, in 13th Annual Green Chemistry and Engineering Conference, Maryland (2009)."},{"key":"83692_CR39","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira, F., Wojnowski, W. & Tobiszewski, M. AGREE\u2014Analytical GREEnness metric approach and software. Anal. Chem. 92, 10076\u201310082 (2020).","journal-title":"Anal. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83692-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83692-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83692-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T18:57:51Z","timestamp":1740077871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83692-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["83692"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83692-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6252"}}